(Q46581957)

23 December 2017

title

Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy (English)

1 reference

23 December 2017

1 reference

George Bakris

1

1 reference

23 December 2017

Ellen Burgess

2

1 reference

23 December 2017

Matthew Weir

3

1 reference

23 December 2017

Giora Davidai

4

1 reference

23 December 2017

Stephen Koval

5

1 reference

23 December 2017

AMADEO Study Investigators

6

1 reference

23 December 2017

language of work or name

English

0 references

publication date

21 May 2008

1 reference

23 December 2017

published in

Kidney International

1 reference

23 December 2017

volume

74

1 reference

23 December 2017

issue

3

1 reference

23 December 2017

page(s)

364-369

1 reference

23 December 2017

https://scigraph.springernature.com/pub.10.1038/ki.2008.204

exact match

0 references

cites work

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Clinical trials report. Combination drug treatment for hypertension with nondiabetic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Effects of combination treatment with losartan and trandolapril on office and ambulatory blood pressures in non-diabetic renal disease: a COOPERATE-ABP substudy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Antihypertensive therapy in the presence of proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Angiotensin II type 1 receptor blockers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

An in-depth review of the evidence linking dietary salt intake and progression of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Rosiglitazone reduces urinary albumin excretion in type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Effects of telmisartan and losartan on insulin resistance in hypertensive patients with metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.204

7 January 2021

Identifiers

DOI

10.1038/KI.2008.204

1 reference

23 December 2017

1 reference

23 December 2017